Table 4. Prognoses of patients with HCC and PVTT treated by transarterial chemotherapy with or without embolization.

Study	Country/region	Enrollment period	Total patients	Treatment characteristics	Median survival, mo.	Overall survival, %
						1 yr	2 yr	3 yr
Ajit 2014	China	2011–2013	85	TACE	7	12	–	–
Chern 2014	Taiwan	2006–2012	50	TACE	11	22	10	8
Choi 2016	Korea	2003–2012	81	TACE	16	81	56	40
Gorodetski 2016	USA	2000–2013	133	TACE	5	48	–	–
Ikeda 2013	Japan	2005–2007	25	TAC	3	40	36	20
Leng 2016	Japan	1997–2012	67	TAC	12	38	20	11
Liu L 2014	China	2006–2012	188	TACE	6	38	17	3
Niu 2012	China	2007–2010	115	TACE	6	40	11
Peng 2012	China	2006–2013	56	TACE	11	38	12	7
Song 2013	Taiwan	2003–2006	39	TAC	7	28	15	13
Tan 2015	China	2000–2008	160	TACE	28 and 15	60,80	41,59	25,37
Tawada 2014	Japan	2000–2010	81	TACE	–	45	23	20
Yang 2014	China	2011–2013	85	TACE	6	12	–	–
Ye 2014	China	2007–2009	338	TACE	13	49	37	19

“–”, data not reported; ca., approximately (for data estimated from published graphs).

Abbreviations: TAC, transarterial chemotherapy; TACE, transarterial chemoembolization.